Management of Restless Legs Syndrome in Chronic Kidney Disease

Initial Assessment and Iron Repletion

The American Academy of Sleep Medicine recommends checking iron studies first in all CKD patients with RLS, measuring morning fasting ferritin and transferrin saturation after avoiding iron supplements for 24 hours 2
For dialysis patients, supplement with IV iron sucrose if ferritin <200 ng/mL AND transferrin saturation <20% (conditional recommendation, moderate certainty) 1
For non-dialysis CKD, consider supplementation if ferritin ≤75 ng/mL OR transferrin saturation <20% 2
The higher ferritin threshold in ESRD reflects altered iron metabolism and inflammation in advanced kidney disease 3, 4

The American Academy of Sleep Medicine conditionally recommends gabapentin for ESRD patients with very low certainty of evidence 2
Start with 100 mg post-dialysis or 100 mg at bedtime for dialysis patients, with a maximum dose of 200-300 mg daily in ESRD 2
Gabapentinoids carry a 31-68% higher risk of altered mental status and falls in dialysis patients, even at low doses 2

Remove stimulants and review medications that worsen RLS, and optimize dialysis adequacy and correct hyperphosphatemia 3, 4
Consider vitamin C supplementation (conditional recommendation, low certainty) specifically for ESRD patients 1
Pneumatic compression devices and good sleep hygiene may also be beneficial 3, 4

Dopamine agonists are NOT recommended as standard treatment due to high risk of augmentation—a paradoxical worsening of symptoms with earlier onset during the day and spread to other body parts 1

Assess iron status and replicate iron if deficient, then start gabapentin with a maximum dose of 200-300 mg daily 1, 2
Consider adding vitamin C supplementation as an adjunct 1
Monitor closely for cognitive changes, falls, and augmentation if any dopaminergic agents are used 1, 2

Extended-release oxycodone and low-dose opioids are conditionally recommended for refractory RLS, though evidence in kidney disease is limited 2
Using standard RLS doses of gabapentin in kidney disease leads to severe toxicity, and doses should be reduced by 70-90% in ESRD 2
RLS in dialysis patients is associated with increased cardiovascular morbidity and mortality, making aggressive symptom management important for overall outcomes 3, 4